This article is more than 5 years old. Information may no longer be current.
Cardiology Today’s top news of November
Cardiology Today compiled a list of the most popular articles posted to Healio.com/Cardiology in November. This month, our readers were interested in the new cholesterol guidelines, the use of sacubitril/valsartan in patients with acute decompensated HF, the CV benefits of dapagliflozin, the results of the VITAL and REDUCE-IT trials and more.
Cholesterol guidelines updated with newer medications, more personalized risk calculation
CHICAGO — New cholesterol guidelines from the American Heart Association, American College of Cardiology and 10 other societies recommend a stepped approach including statins, ezetimibe and PCSK9 inhibitors in patients with prior CVD at very high risk for another event.
PIONEER-HF: Sacubitril/valsartan superior to enalapril in acute decompensated HF
CHICAGO — Patients with acute decompensated HF had greater reduction in N-terminal pro-B-type natriuretic peptide when assigned sacubitril/valsartan (Entresto, Novartis) than treatment with enalapril, according to the results of the PIONEER-HF trial presented at the AHA Scientific Sessions.
DECLARE-TIMI 58: Dapagliflozin reduces HF hospitalization in type 2 diabetes
CHICAGO — The DECLARE-TIMI 58 trial of dapagliflozin (Farxiga, AstraZeneca) in patients with type 2 diabetes who had or were at high risk for atherosclerotic CVD adds to the growing body of evidence demonstrating the favorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on CV risk.
Read More
VITAL: Mixed findings for vitamin D, omega-3s in CVD, cancer prevention
CHICAGO — In the large-scale VITAL trial, neither omega-3 nor vitamin D supplements for primary prevention reduced major CV events or development of invasive cancers compared with placebo over 5 years of follow-up, but some secondary endpoints showed promising signals.
REDUCE-IT: Icosapent ethyl reduces ischemic events in high-risk patients
CHICAGO — In patients with elevated triglycerides at high CV risk despite statin therapy, icosapent ethyl was superior to placebo for reducing risk for ischemic events, according to results of the anticipated REDUCE-IT trial.
SGLT2 inhibitor prescription rates low among cardiologists
At a major tertiary care center, cardiologists prescribed only about 5% of all SGLT2 inhibitors from 2013 to 2017, with no appreciable increase after the FDA expanded labeling for use of these agents for CV risk reduction, researchers reported in the Journal of the American College of Cardiology.
New physical activity guidelines encourage movement ‘anytime, anywhere’
CHICAGO — At the AHA Scientific Sessions, HHS released the second edition of the Physical Activity Guidelines for Americans, which provides new recommendations for children and adolescents aged 3 to 17 years.
New advances in preventive cardiology: A critical appraisal of 2018 cholesterol guidelines
The AHA and the ACC, in collaboration with multiple other societies, recently published two highly significant documents in the field of preventive cardiology: Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease, henceforth called Risk Assessment Statement, and the 2018 Guideline on the Management of Blood Cholesterol, henceforth called Cholesterol Guidelines.
Herein, we discuss the new guidelines with special focus on four objectives: to examine the key changes from previous recommendations; to summarize the evidence from the primary studies that led to these changes; highlight recommendations that were maintained and strengthened; and to discuss points where the guideline recommendations could be further improved.
PRINCESS: Transnasal cooling safe, may improve outcomes in out-of-hospital cardiac arrest
CHICAGO — Transnasal evaporative cooling initiated during CPR in patients with out-of-hospital cardiac arrest before they arrived at the hospital was hemodynamically safe as it shortened the time to target temperature, according to data presented at the AHA Scientific Sessions.
Low-dose rivaroxaban reduces thromboembolic events in HF
CHICAGO — In a post hoc analysis of the COMMANDER HF trial, treatment with low-dose rivaroxaban (Xarelto, Bayer/Janssen) reduced risk for thromboembolic events in patients with worsening of chronic HF, reduced ejection fraction, CAD and sinus rhythm.